Zoetis Inc. (NYSE:ZTS – Get Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 4,960,000 shares, a growth of 22.5% from the April 15th total of 4,050,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 1.1% of the company’s stock are sold short.
Shares of NYSE ZTS opened at $166.43 on Wednesday. The firm’s 50-day simple moving average is $183.62 and its 200 day simple moving average is $202.80. The stock has a market cap of $78.33 billion, a P/E ratio of 38.17, a P/E/G ratio of 2.77 and a beta of 0.77. The company has a quick ratio of 1.58, a current ratio of 2.25 and a debt-to-equity ratio of 1.12. Zoetis has a fifty-two week low of $158.27 and a fifty-two week high of $249.27.
Zoetis (NYSE:ZTS – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.09. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period in the prior year, the business posted $1.26 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Zoetis will post 5.06 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of ZTS. Worldquant Millennium Advisors LLC acquired a new position in Zoetis during the first quarter worth about $19,287,000. Walleye Capital LLC acquired a new position in shares of Zoetis in the 1st quarter worth $446,000. Continuum Advisory LLC raised its position in shares of Zoetis by 15.4% during the first quarter. Continuum Advisory LLC now owns 4,213 shares of the company’s stock worth $747,000 after purchasing an additional 562 shares during the period. Avalon Investment & Advisory acquired a new position in shares of Zoetis in the 1st quarter valued at $293,000. Finally, Virtu Financial LLC purchased a new position in Zoetis in the 1st quarter worth about $2,896,000. Institutional investors own 90.73% of the company’s stock.
Several analysts recently weighed in on ZTS shares. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Citigroup lowered their price target on Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a report on Wednesday, March 9th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $235.29.
Zoetis Company Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.